Novapeutics LLC

PO Box 521
Metuchen, New Jersey

Booth: 714

Oral presenter


Treating type 2 diabetes using menin inhibitors to regenerate insulin producing beta cells

Technology Area: Pharmaceuticals & Personal Care

Commercial Maturity: Prototype

Abstract: We are developing a novel small molecule diabetes therapeutic to enhance endogenous insulin producing beta cell regeneration in diabetes patients. We are determining the impact of the identified lead compounds (CDH1‐2) on beta cell regeneration and to optimize improved compounds based on the crystal structure of drug target menin.